San Francisco, CA, United States of America

Douglas Michael Ackermann

This inventor holds 34 USPTO granted patents and 13 published patent applications and 14 EPO patents, primarily in Ocular Health Devices. Top assignees: Oculeve, Inc., Leland Stanford Junior University, Boston Scientific Neuromodulation Corporation. Active years: 2014-2025.

USPTO Granted Patents = 34 

% Patents Active = 79.4

 

Average Co-Inventor Count = 3.9

ph-index = 17

Forward Citations = 833(Granted Patents)


Location History:

  • Palo Alto, CA (US) (2014 - 2017)
  • San Francisco, CA (US) (2015 - 2023)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Contact Lens
Hydrophilic Layer
Nasal Stimulation
Dry Eye Treatment
Ocular Allergies
Tear Production
Implantable Devices
Pharmaceutical Formulations
Nasal Stimulator
Ocular Conditions
Animal Treatments
Stimulation Devices
34 patents (USPTO):Explore Patents

Title: Douglas Michael Ackermann - Innovative Inventor from San Francisco

Introduction: Douglas Michael Ackermann is a renowned inventor based in San Francisco, CA, known for his groundbreaking contributions to various industries.

Latest Patents: Douglas Michael Ackermann holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise.

Career Highlights: With over two decades of experience in the innovation sector, Douglas Michael Ackermann has led numerous successful projects that have revolutionized the way we approach everyday challenges.

Collaborations: Throughout his career, Douglas Michael Ackermann has collaborated with leading companies, research institutions, and universities to bring his inventions to life and make a lasting impact on society.

Conclusion: Douglas Michael Ackermann's passion for innovation and his dedication to creating a better future through his inventions make him a true pioneer in the world of technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…